News

Initial results from the collaboration showed positive results in using RXi’s proprietary self-delivering rxRNA (sd-rxRNA) compounds to silence genes up to 80% in hemopoietic cells. The companies said

Rivaroxaban is an oral direct Factor Xa inhibitor, which is being jointly developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD). The submission

The trial will evaluate the efficacy of Erbitux in combination with cisplatin and capecitabine chemotherapies as a first line treatment for patients with advanced/metastatic gastric adenocarcinoma, including gastroesophageal

StayinFront claims that StayinFront EdgeRx, a multi-lingual on-demand CRM with integrated analytic capabilities, offers flexibility to access the syatem online or offline featuring. Archimedes Pharma Global CIO Demi

Rituximab is a cancer (antineoplastic) medication which works by interfering with the growth of cancer cells by slowing their growth and spread in the body. Rituximab is also

The GORE C3 Delivery System allows physicians and interventionalists to reposition the Gore Excluder Device before the final release of the delivery catheter. The deployment control of the

The data from CVBT’s Phase II trial suggested that CVBT’s FGF-1 biological drug showed efficacy at a level greater than has been seen in any other treatments, for

As per the terms of the agreement, ImmunGene is entitled to get undisclosed fees which include upfront payment from Cephalon Australia a four-year option to leverage ImmunGene’s novel

Under the pact, Kinaxo will make use of high-end mass spectrometry-based technologies to quantitatively evaluate posttranslational protein modifications on a proteome-wide scale. Kinaxo CTO Henrik Daub said that